Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax turns negative

Q1 FY2026 income before tax was -$8.93M, compared with $6.11M a year earlier. Trailing-twelve-month income before tax was -$18.76M.

Context

  • Income before tax amounted to 1.6% of revenue in FY2025, down 41.8 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$8.93M or moves back toward the trailing-twelve-month quarterly average of -$4.69M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.93M+20.5% QoQ
Last fiscal yearDec 2025
-$3.72M+94.6% YoY
LTMMar 2026
-$18.76M+58.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-246.1%——
1 year+94.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(3.72M) USD
Year-over-year change
+94.6%

Income Before Tax vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 income before tax of -$18.76M is the 3rd highest of the 10 companies compared; the peer median is -$105.99M.
  • Its year-over-year change of +58.6% is the 3rd highest of 9, against a peer median of +0.9%.
  • Income before tax amounts to 8.1% of revenue for AKBA, versus a peer median of 152.1%.
AKBA Competitors Peer median
Income Before Tax for AKBA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$133.4M +277.0%—109.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$121.97M +219.9%—40.7%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$18.76M +58.6%—8.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M -6.7%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$68.17M -23.5%——
PRTAProthena Corporation plcLTM Mar 2026-$105.99M +8.5%—182.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$141.22M ——121.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$160.9M +8.8%—182.3%
GOSSGossamer Bio, Inc.LTM Mar 2026-$180.48M -258.5%—325.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$185.15M -43.6%——
Peer median (excluding AKBA) -$105.99M+0.9%—152.1%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.